FR2840810B1 - Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires - Google Patents

Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires

Info

Publication number
FR2840810B1
FR2840810B1 FR0207493A FR0207493A FR2840810B1 FR 2840810 B1 FR2840810 B1 FR 2840810B1 FR 0207493 A FR0207493 A FR 0207493A FR 0207493 A FR0207493 A FR 0207493A FR 2840810 B1 FR2840810 B1 FR 2840810B1
Authority
FR
France
Prior art keywords
lungs
transfer
treatment
composition
lung cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0207493A
Other languages
English (en)
Other versions
FR2840810A1 (fr
Inventor
Jamal Temsamani
Anthony R Rees
Christophe Rousselle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synt EM SA
Original Assignee
Synt EM SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0207493A priority Critical patent/FR2840810B1/fr
Application filed by Synt EM SA filed Critical Synt EM SA
Priority to PCT/FR2003/001864 priority patent/WO2003105907A2/fr
Priority to AU2003258813A priority patent/AU2003258813A1/en
Priority to CA002488879A priority patent/CA2488879A1/fr
Priority to JP2004512807A priority patent/JP2006517177A/ja
Priority to EP03760057A priority patent/EP1513557A2/fr
Publication of FR2840810A1 publication Critical patent/FR2840810A1/fr
Priority to IL16557404A priority patent/IL165574A0/xx
Priority to US11/016,318 priority patent/US20050159360A1/en
Application granted granted Critical
Publication of FR2840810B1 publication Critical patent/FR2840810B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR0207493A 2002-06-18 2002-06-18 Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires Expired - Fee Related FR2840810B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0207493A FR2840810B1 (fr) 2002-06-18 2002-06-18 Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
AU2003258813A AU2003258813A1 (en) 2002-06-18 2003-06-18 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
CA002488879A CA2488879A1 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons, et leur utilisation pour leur traitement des cancers du poumon et des maladies pulmonaires
JP2004512807A JP2006517177A (ja) 2002-06-18 2003-06-18 肺へ治療分子を輸送する組成物、並びに肺がん及び肺疾患治療のためのその使用
PCT/FR2003/001864 WO2003105907A2 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
EP03760057A EP1513557A2 (fr) 2002-06-18 2003-06-18 Compositions pour le transport de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
IL16557404A IL165574A0 (en) 2002-06-18 2004-12-06 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases
US11/016,318 US20050159360A1 (en) 2002-06-18 2004-12-17 Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0207493A FR2840810B1 (fr) 2002-06-18 2002-06-18 Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires

Publications (2)

Publication Number Publication Date
FR2840810A1 FR2840810A1 (fr) 2003-12-19
FR2840810B1 true FR2840810B1 (fr) 2005-02-11

Family

ID=29595347

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0207493A Expired - Fee Related FR2840810B1 (fr) 2002-06-18 2002-06-18 Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires

Country Status (8)

Country Link
US (1) US20050159360A1 (fr)
EP (1) EP1513557A2 (fr)
JP (1) JP2006517177A (fr)
AU (1) AU2003258813A1 (fr)
CA (1) CA2488879A1 (fr)
FR (1) FR2840810B1 (fr)
IL (1) IL165574A0 (fr)
WO (1) WO2003105907A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968662B1 (fr) 2010-12-10 2013-11-22 Roussy Inst Gustave Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
EP2896400A1 (fr) 2014-01-17 2015-07-22 Université Catholique De Louvain Procédé pour augmenter la biodisponibilité de composés inhalés

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2767323B1 (fr) * 1997-08-12 2001-01-05 Synt Em Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
EP1210121A2 (fr) * 1999-08-24 2002-06-05 Cellgate Inc. Compositions et procedes ameliorant la diffusion de medicaments a travers et dans des tissus epitheliaux
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
AU2002340561B2 (en) * 2001-10-16 2007-11-15 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens

Also Published As

Publication number Publication date
WO2003105907A2 (fr) 2003-12-24
WO2003105907A3 (fr) 2004-04-22
JP2006517177A (ja) 2006-07-20
US20050159360A1 (en) 2005-07-21
CA2488879A1 (fr) 2003-12-24
FR2840810A1 (fr) 2003-12-19
IL165574A0 (en) 2006-01-15
AU2003258813A1 (en) 2003-12-31
EP1513557A2 (fr) 2005-03-16

Similar Documents

Publication Publication Date Title
DE50311502D1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
NO20022174D0 (no) Anvendelse av anti-CD40L-antistoff i kombinasjon med anti- CD20-antistoff og/eller kjemoterapeutika og radioterapi vedbehandling av B-cellesykdommer
EE200100372A (et) TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
IL174698A0 (en) Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
NO20041588L (no) Anvendelse av flibanserin ved behandling av seksuelle forstyrrelser
NO20022680L (no) Farmasoytiske kombinasjoner og deres anvendelse ved behandling av gastrointestinale forstyrrelser
ME00425B (me) Liječenje sa anti-vegf antitijelima
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
FR2906808B1 (fr) Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
NO20043370L (no) N-pyrazinylfenylsulfonamider og deres anvendelse ved behandling av kemokinmedierte sykdommer
IL178775A (en) Pharmaceuticals containing glucocorticoid for use in the treatment of disorders requiring acute glucocorticoid therapy
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
MX2007009810A (es) Uso de interleucina-17f en diagnostico y terapia de inflamacion de vias aereas.
NO20034437D0 (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
BR9709097A (pt) Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
AU2003260484A1 (en) Method for improving the ability of patients suffering from lung diseases to participate in and benefit from pulmonary rehabilitation programs
NO20001412D0 (no) Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
NO20030295L (no) Anvendelse av derivater av valproinsyre- og 2- valproensyreamider for behandling av manier ved bipolare lidelser
EP1605950A4 (fr) Nouvelles entites chimiques et leurs methodes d'utilisation dans le traitement de troubles du metabolisme
AU2003265620A8 (en) Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
FR2840810B1 (fr) Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
EP1776126A4 (fr) Methodes d'utilisation de cellules regeneratrices dans le traitement d'accident vasculaire cerebral et de maladies et de troubles lies

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100226